Table 3. Clinical features of PNH and... | American Society of Hematology

Table 3.

Clinical features of PNH⁺ and PNH⁻RA patients

	PNH⁺ RA	PNH⁻ RA	P
Incidence of karyotypic abnormalities (%)	1 of 21 (4.8)	21 of 64 (32.8)	.01^3-150
Neutrophils with the Pseudo-Pelger-Hüet anomaly, % (range)	2.0 (0-35.0)	6.0 (0.5-45.2)	.02^3-151
Platelet count, 10⁹/L (range)	31 (4-121)	91 (9-126)	.01^3-151
Incidence of HLA-DR15 (DRB1^3-1501501 and DRB1^3-1501502) (%)	19 of 21 (90.5)	5 of 27 (18.5)	<.001^3-150
Response to cyclosporine therapy (%)	7 of 9 (77.8)	0 of 8 (0)	.002^3-150
Progression to advanced MDS or AML (%)	0 of 21 (0)	4 of 65 (6.2)	.57^3-150

	PNH⁺ RA	PNH⁻ RA	P
Incidence of karyotypic abnormalities (%)	1 of 21 (4.8)	21 of 64 (32.8)	.01^3-150
Neutrophils with the Pseudo-Pelger-Hüet anomaly, % (range)	2.0 (0-35.0)	6.0 (0.5-45.2)	.02^3-151
Platelet count, 10⁹/L (range)	31 (4-121)	91 (9-126)	.01^3-151
Incidence of HLA-DR15 (DRB1^3-1501501 and DRB1^3-1501502) (%)	19 of 21 (90.5)	5 of 27 (18.5)	<.001^3-150
Response to cyclosporine therapy (%)	7 of 9 (77.8)	0 of 8 (0)	.002^3-150
Progression to advanced MDS or AML (%)	0 of 21 (0)	4 of 65 (6.2)	.57^3-150

Progression to advanced disease was observed for 2.5 years.

Fisher exact test;

Mann-Whitney U test.